| Literature DB >> 32257418 |
Timothy Bebe1, Babatunde Odetoyin1, Rahman Bolarinwa2.
Abstract
OBJECTIVES: We sought to determine the prevalence of asymptomatic bacteriuria (ASB) in patients with sickle cell disease (SCD), the susceptibility profile of its agents and their extended-spectrum β-lactamase (ESBL) production.Entities:
Keywords: Anemia, Sickle Cell; Anti-Bacterial Agents; Bacteriuria; Drug Resistance
Year: 2020 PMID: 32257418 PMCID: PMC7105804 DOI: 10.5001/omj.2020.27
Source DB: PubMed Journal: Oman Med J ISSN: 1999-768X
Primers used for sequencing of ESBL genes by PCR.
| Genes | Primer | Sequence (5´- 3´) | Size (bp) |
|---|---|---|---|
| SHV | SHV-F | CGCCTGTGTATTATCTCCCT | 293 |
| SHV-R | CGAGTAGTCCACCAGATCCT | ||
| TEM | TEM-F | TTTCGTGTCGCCCTTATTCC | 403 |
| TEM-R | ATCGTTGTCAGAAGTAAGTTGG | ||
| CTX-M | CTX-M-F | CGCTGTTGTTAGGAAGTGTG | 874 |
| CTX-M-R | GGCTGGGTGAAGTAAGTGAC |
ESBL: extended spectrum beta-lactamase PCR: polymerase chain reaction.
Demographic characteristics of the study participants.
| Variables | Patients with SCD | HbAA controls | p-value |
|---|---|---|---|
| Gender | 0.628* | ||
| Male | 23 (39.7) | 51 (44.0) | |
| Female | 35 (60.3) | 65 (56.0) | |
| Mean age, mean ± SD, years | 25.0 ± 8.1 | 24.0 ± 4.0 | 0.195§ |
| Age group, years | 0.005* | ||
| ≥ 30 | 15 (25.9) | 10 (9) | |
| < 30 | 43 (74.1) | 106 (91) | |
| Education level | < 0.010* | ||
| Secondary | 14 (24.1) | 0 (0.0) | |
| Tertiary | 44 (75.9) | 116 (100) | |
| Marital status | 0.183* | ||
| Single | 52 (98.7) | 111 (95.7) | |
| Married | 6 (10.3) | 5 (4.3) |
*Fisher’s exact probability test
§Mann-Whitney U test
Mann-Whitney U (Z) = 2959.000
SCD: sickle cell disease; SD: standard deviation; HbAA: hemoglobin AA.
Prevalence of asymptomatic bacteriuria (ASB) in the study population.
| Parameters | Patients with SCD | HbAA controls | ||
|---|---|---|---|---|
| Frequency (total) | % | Frequency (total) | % | |
| Overall ASB prevalence | 5 (58) | 8.6 | 1 (116) | 0.9 |
| ASB prevalence in males | 0 (23) | 0.0 | 0 (51) | 0.0 |
| ASB prevalence in females | 5 (35) | 14.3 | 1 (65) | 1.5 |
SCD: sickle cell disease; HbAA: hemoglobin AA.
Prevalence of asymptomatic bacteriuria (ASB) in relation to gender, age, marital status, and educational level.
| Parameters | ASB | Total | PR | 95% CI | p-value | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Gender | - | - | 0.146 | |||
| Female | 5 (14.3) | 30 (85.7) | 35 (100) | |||
| Male | 0 (0.0) | 23 (100) | 23 (100) | |||
| Total | 5 (8.6) | 53 (91.4) | 58 (100) | |||
| Age, years | 1.911 | 0.353–10.356 | 0.596 | |||
| ≥ 30 | 2 (13.3) | 13 (86.7) | 15 (100) | |||
| < 30 | 3 (7.0) | 40 (93.0) | 43 (100) | |||
| Total | 5 (8.6) | 53 (91.4) | 58 (100) | |||
| Marital status | 5.778 | 1.194–27.968 | 0.023* | |||
| Married | 2 (33.3) | 4 (66.7) | 6 (100) | |||
| Single | 3 (5.8) | 49 (94.2) | 52 (100) | |||
| Total | 5 (8.6) | 53 (91.4) | 58 (100) | |||
| Education level | 4.714 | 0.874–25.424 | 0.085 | |||
| Secondary | 3 (21.4) | 11 (78.6) | 14 (100) | |||
| Tertiary | 2 (4.5) | 42 (95.5) | 44 (100) | |||
| Total | 5 (8.6) | 53 (91.4) | 58 (100) | |||
*Significance at p < 0.05.
PR: prevalence; CI: confidence interval.
Resistance index, resistance pattern of MDR uropathogens, and ESBL genes present in the ESBL producing isolate.
| Organisms | Number of antibiotics tested | MAR index | Number of classes of antibiotics tested | Number to which isolates were resistant | ESBL genes | Variant | Resistance pattern |
|---|---|---|---|---|---|---|---|
| Gram-positive isolates | |||||||
| 19 | 0.47 | 12 | 5 | None | NA | CTX, CAZ, CRO, FEP, PEN, AMP, STR, TET, STX. | |
| 19 | 0.68 | 12 | 7 | None | NA | CTX, CAZ, CRO, FEP, CEF, PEN, AMP, CIP, STR, TET, CHL, STX, NOR | |
| 19 | 0.42 | 12 | 5 | None | NA | CAZ, FEP, PEN, AMP, STR, TET, CHL, STX | |
| Gram-negative isolates | |||||||
| 17 | 0.47 | 11 | 5 | None | NA | CTX, CAZ, CRO, PEN, AMP, TET, F, ERY | |
| 17 | 0.53 | 11 | 6 | None | NA | CTX, CAZ, CRO, PEN, AMP, TET, F, CHL, ERY | |
| 18 | 0.95 | 11 | 10 | CTX-M, TEM, SHV | CTX-M-15 | CTX, CAZ, CRO, FEP, AMC, PEN, AMP, CIP, STR, TET, F, CHL, C, STX, ERY, OFL, NOR | |
| 17 | 0.65 | 11 | 8 | None | NA | CTX, CAZ, CRO, AMC, PEN, AMP, STR, TET, F, CHL, ERY |
*from control.
MDR: multi-drug resistance; ESBL: extended-spectrum β-lactamase; NA: not applicable; MAR: multiple antibiotic-resistant; CTX: cefotaxime; CAZ: ceftazidime; CRO: ceftriaxone; FEP: cefepime; AMC: amoxicillin-clavulanic acid; PEN: penicillin; AMP: ampicillin; CIP: ciprofloxacin; STR: streptomycin; TET: tetracycline; F: nitrofurantoin; CHL: chloramphenicol; C: gentamicin; STX: trimethoprim-sulfamethoxazole; ERY: erythromycin; OFL: ofloxacin; NOR: norfloxacin.*Significance at p < 0.050.
Figure 1Polymerase chain reaction amplification of SHV (293bp), TEM (403bp), and CTX-M (874bp). Lane L: 100bp DNA-ladder, lane 1: Enterobacter cloacae (SHV, TEM and CTX-M), lane 2: Enterobacter cloacae (CTX-M), and Lane 3: Enterobacter cloacae (TEM).